The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study
- PMID: 18986508
- PMCID: PMC2596771
- DOI: 10.1186/1741-7015-6-32
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study
Abstract
Background: We report age-dependent penetrance estimates for leucine-rich repeat kinase 2 (LRRK2)-related Parkinson's disease (PD) in a large sample of familial PD. The most frequently seen LRRK2 mutation, Gly2019Ser (G2019S), is associated with approximately 5 to 6% of familial PD cases and 1 to 2% of idiopathic cases, making it the most common known genetic cause of PD. Studies of the penetrance of LRRK2 mutations have produced a wide range of estimates, possibly due to differences in study design and recruitment, including in particular differences between samples of familial PD versus sporadic PD.
Methods: A sample, including 903 affected and 58 unaffected members from 509 families ascertained for having two or more PD-affected members, 126 randomly ascertained PD patients and 197 controls, was screened for five different LRRK2 mutations. Penetrance was estimated in families of LRRK2 carriers with consideration of the inherent bias towards increased penetrance in a familial sample.
Results: Thirty-one out of 509 families with multiple cases of PD (6.1%) were found to have 58 LRRK2 mutation carriers (6.4%). Twenty-nine of the 31 families had G2019S mutations while two had R1441C mutations. No mutations were identified among controls or unaffected relatives of PD cases. Nine PD-affected relatives of G2019S carriers did not carry the LRRK2 mutation themselves. At the maximum observed age range of 90 to 94 years, the unbiased estimated penetrance was 67% for G2019S families, compared with a baseline PD risk of 17% seen in the non-LRRK2-related PD families.
Conclusion: Lifetime penetrance of LRRK2 estimated in the unascertained relatives of multiplex PD families is greater than that reported in studies of sporadically ascertained LRRK2 cases, suggesting that inherited susceptibility factors may modify the penetrance of LRRK2 mutations. In addition, the presence of nine PD phenocopies in the LRRK2 families suggests that these susceptibility factors may also increase the risk of non-LRRK2-related PD. No differences in penetrance were found between men and women, suggesting that the factors that influence penetrance for LRRK2 carriers are independent of the factors which increase PD prevalence in men.
Figures
Comment in
-
LRRK2 in Parkinson's disease - drawing the curtain of penetrance: a commentary.BMC Med. 2008 Nov 5;6:33. doi: 10.1186/1741-7015-6-33. BMC Med. 2008. PMID: 18986509 Free PMC article.
-
Penetrance of LRRK2 mutations in familial Parkinson disease.Nat Clin Pract Neurol. 2009 Mar;5(3):120. Nat Clin Pract Neurol. 2009. PMID: 20408266 No abstract available.
Similar articles
-
Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients.Parkinsonism Relat Disord. 2009 May;15(4):277-80. doi: 10.1016/j.parkreldis.2008.06.009. Epub 2008 Sep 20. Parkinsonism Relat Disord. 2009. PMID: 18805725
-
LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study.Lancet Neurol. 2008 Jul;7(7):591-4. doi: 10.1016/S1474-4422(08)70116-9. Epub 2008 Jun 6. Lancet Neurol. 2008. PMID: 18539535
-
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.Lancet Neurol. 2008 Jul;7(7):583-90. doi: 10.1016/S1474-4422(08)70117-0. Epub 2008 Jun 6. Lancet Neurol. 2008. PMID: 18539534 Free PMC article.
-
LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson's disease.Neurochem Res. 2007 Oct;32(10):1700-8. doi: 10.1007/s11064-007-9324-y. Epub 2007 Apr 18. Neurochem Res. 2007. PMID: 17440812 Review.
-
LRRK2 G2019S in the North African population: a review.Eur Neurol. 2010;63(6):321-5. doi: 10.1159/000279653. Epub 2010 Apr 23. Eur Neurol. 2010. PMID: 20413974 Review.
Cited by
-
Review of the epidemiology and variability of LRRK2 non-p.Gly2019Ser pathogenic mutations in Parkinson's disease.Front Neurosci. 2022 Sep 20;16:971270. doi: 10.3389/fnins.2022.971270. eCollection 2022. Front Neurosci. 2022. PMID: 36203807 Free PMC article. Review.
-
Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation.Biochemistry. 2010 Jul 6;49(26):5511-23. doi: 10.1021/bi100157u. Biochemistry. 2010. PMID: 20515039 Free PMC article.
-
The genetics of Parkinson's disease: progress and therapeutic implications.Mov Disord. 2013 Jan;28(1):14-23. doi: 10.1002/mds.25249. Mov Disord. 2013. PMID: 23389780 Free PMC article. Review.
-
Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease.Neurobiol Aging. 2018 Apr;64:159.e5-159.e8. doi: 10.1016/j.neurobiolaging.2017.12.012. Epub 2017 Dec 20. Neurobiol Aging. 2018. PMID: 29398121 Free PMC article.
-
Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease.Ann Neurol. 2021 Jul;90(1):76-88. doi: 10.1002/ana.26094. Epub 2021 May 17. Ann Neurol. 2021. PMID: 33938021 Free PMC article.
References
-
- Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, Brug M van der, Lopez de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, Singleton AB. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 2004;44:595–600. doi: 10.1016/j.neuron.2004.10.023. - DOI - PubMed